Recombinant Human Interleukin 1 Family, Member 7, His-tagged
|Product Overview :
|Recombinant Human IL1F7 encoding the human IL1F7 Isoform B (Val46–Asp218) was expressed inE.coli. It was recombined with a Hexa-his N-Terminus and purified by Nicolumn.MW=19.3 KD.
- Gene Information
- Related Products
|Cat. No. :
|IL-1F7 binds to interleukin-18 receptor (IL-18R) receptor but not to IL-1 receptor. That Could be a new player in the inflammatory and immune responses mediated by the IL-18/IL-18R axis. IL1F7 isoform B were expressed in testis, colon, placenta, lung and lymph node. It was reported that isoform B were expressed in kidney.
|Human IL1F7 isoform B (Val46–Asp218)46 VHTSPKVKNL NPKKFSIHDQ DHKVLVLDSG NLIAVPDKNY IRPEIFFALA SSLSSASAEK GSPILLGVSK GEFCLYCDKD KGQSHPSLQL KKEKLMKLAA QKESARRPFI FYRAQVGSWN MLESAAHPGW FICTSCNCNE PVGVTDKFEN RKHIEFSFQP VCKAEMSPSE VSD 216
|Lyophilized 100μg humanIL1F7 in 50μl of TBS (20mM Tris, 50mM NaCl, pH8.0). Carry free.
|>95% by SDS gel.
|Add 500μl deionized water to the vial to prepare a working stock solution at 200μg/mL . Allow to set at least 30 minutes at 4℃, mix well.
|Store lyophilized protein at -20℃ or -70℃. Lyophilized protein is stable for up to 6 months from date of receipt at -20℃ to -70℃. Upon reconstitution, this protein can be stored at -20℃ for a few weeks or at -70℃ in a manual defrost freezer for long term storage (six months). Aliquot reconstituted protein to avoid repeated freezing / thawing cycles.
|◆ Recombinant Protein
|Recombinant Human IL37 Protein, His (Fc)-Avi-tagged
|Active Recombinant Human IL37 Protein (Lys53-Asp218), C-His tagged, Animal-free, Carrier-free
|Recombinant Active Human IL37 Protein, His-tagged(C-ter)
|Recombinant Human IL37 Protein, DYKDDDDK-tagged
|Recombinant Human IL37 protein
|Recombinant Human IL1F7 293 Cell Lysate
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The safety and efficacy of recombinant IL37 in children have not been established and need to be validated in further studies.
The IL37 works by inhibiting the release of inflammatory mediators and regulating immune cell levels, thereby reducing the inflammatory response.
The length of treatment for IL37 varies depending on the severity of the disease and the patient's response, and generally requires long-term treatment.
At present, there is not enough evidence to show that IL37 can be used to prevent inflammatory diseases, and further studies are needed to verify it.
IL37 has anti-inflammatory and immunomodulatory effects, and may have a certain effect on allergic diseases, but further studies are needed to verify it.
IL37 is currently mainly administered by injection, and oral administration studies are still under way.
Customer Reviews (3)Write a review
IL37 has a long half-life and is able to maintain stability and reliability during experiments.
When using IL37 protein for experiments, it can meet specific experimental requirements and research purposes.
IL37 products have a complete range of specifications and are suitable for experimental designs of different sizes and needs.
Ask a Question for All IL37 Products
Required fields are marked with *
My Review for All IL37 Products
Required fields are marked with *